Anaphylaxis Uncertainty Lingers For Merck's Sugammadex
This article was originally published in Scrip
Executive Summary
Merck & Co.'s modified gamma-cyclodextrin agent sugammadex, which is under review at the FDA for the fourth time, is headed back to the agency's advisory committee on Nov. 6 for another go-around on whether the experts think the product is finally ready for the market.